A confirmed history of syphilis disqualifies you from donating plasma at most blood collection centers, and that deferral is usually permanent. Even after successful antibiotic treatment, the antibodies your body produced against the syphilis-causing bacterium tend to linger for life, and current screening tests cannot reliably distinguish a cured past infection from an active one. This creates a frustrating situation for people who were treated years ago and pose no actual transmission risk, but the biology of both the pathogen and the testing technology makes it difficult for blood banks to confidently clear you.
Why Blood Banks Care About Syphilis at All
Syphilis is caused by the bacterium Treponema pallidum, and while it is primarily a sexually transmitted infection, it can also be passed through blood products. The bacterium survives in stored blood longer than many people assume. A 2021 study found that viable T. pallidum survived for seven days in whole blood and six days in platelets, whether stored at room temperature or refrigerated.1PubMed Central. Effect of Storage on Survival of Infectious Treponema pallidum Spiked in Whole Blood and Platelets Older research suggested the bacterium dies off after about 72 hours in cold-stored blood, and that number still gets cited in guidelines, but more recent work shows the window may be wider depending on the initial bacterial load and storage conditions.2PubMed Central. Survival of Treponema pallidum in banked blood for prevention of Syphilis transmission
A systematic review and meta-analysis confirmed that storing artificially infected blood for more than 72 hours significantly reduced the number of animals that developed syphilis after receiving the blood, but did not eliminate the risk entirely. Transmission remained possible for up to seven days. And for plasma specifically, the picture was less reassuring: the researchers found no significant reduction in transmission risk from stored rabbit plasma.3PubMed. Does cold storage of blood before transfusion prevent the transmission of syphilis? A systematic review and meta-analysis Fresh frozen plasma and platelets stored at room temperature pose what researchers call a “theoretical risk” of syphilis transmission, which is one reason screening and deferral policies remain strict.4PubMed Central. Syphilis testing in blood donors: an update
The Antibody Problem After Treatment
Here is the core frustration for anyone who was treated for syphilis and now wants to donate: the most sensitive screening tests look for antibodies your immune system made against T. pallidum itself, and those antibodies often stick around for the rest of your life even after the infection is completely gone. Blood centers know this. As one review put it, treponemal tests often remain reactive for life in people with a history of adequately treated syphilis, while nontreponemal tests usually become nonreactive over time.4PubMed Central. Syphilis testing in blood donors: an update This leaves blood centers in a bind: they can either defer donors who carry harmless leftover antibodies and are not infectious, or adopt more complex testing workflows to sort out past infections from current ones. Most centers choose the simpler path and defer indefinitely.
Nontreponemal tests like the RPR (rapid plasma reagin) do tend to decline and eventually turn negative after treatment. Doctors use these to monitor whether treatment worked. But the timeline is unpredictable. A retrospective study of syphilis patients in Tokyo found that RPR titers varied widely even before treatment began, and the rate of decline after treatment depended on the stage of infection and other health factors.5PLOS ONE. Changes in rapid plasma reagin titers in patients with syphilis before and after treatment A negative RPR combined with a positive treponemal test is consistent with a treated past infection, but confirming that picture requires follow-up over months, which is not something a blood bank screening program is set up to do.
How Screening Works at Blood Centers
Most blood collection centers worldwide now use what is called a “reverse algorithm” for syphilis screening. Instead of starting with an older nontreponemal test like RPR, they lead with a treponemal test, typically an automated immunoassay that detects both IgM and IgG antibodies against T. pallidum. If that test comes back reactive, the sample gets follow-up testing.
The logic behind the reverse algorithm is straightforward: automated treponemal tests are more sensitive and catch more cases, including very early infections where nontreponemal tests might still be negative. A study in Coastal Karnataka, India, found that using the reverse algorithm increased the detected syphilis prevalence compared to the older screening strategy, with a positive predictive value around 78 to 89 percent depending on the platform used.6Transfusion Clinique et Biologique. Reverse algorithm for screening of syphilis and trends in prevalence among blood donors in Coastal Karnataka Reactive samples then get tested by RPR to assess whether the infection is active and by a second treponemal test like TPHA to resolve discordant results.7Panacea Journal of Medical Sciences. Comparison of syphilis testing by reverse algorithm and conventional method among blood donors in a tertiary care center
The catch is that the very sensitivity of these treponemal screening tests is what makes them flag people with old, treated infections. If you had syphilis ten years ago and completed treatment, your treponemal antibodies will likely trigger the initial screen. The follow-up RPR might be negative, which is consistent with a cured infection, but many centers still defer you permanently because the treponemal test is positive.
How Deferral Policies Differ Around the World
There is no single global standard for what happens after a positive syphilis screen. A worldwide survey of blood donation screening practices found that nearly all institutions screen universally for syphilis (35 out of 36 surveyed), but there was substantial variation in confirmatory testing, deferral criteria, and whether donors could ever return to donating. Most centers apply indefinite deferral.8PubMed. Mapping syphilis surveillance: Insights into blood donation screening practices worldwide
In France, for example, European Directive 2002/98/EC technically allows a one-year deferral after a confirmed cure, but because certifying a cure would require putting donors through repeated follow-up testing, French blood authorities apply permanent exclusion once a donor is confirmed positive.9PubMed Central. Syphilis testing in blood donors, France, 2007 to 2022 The practical difficulty of proving cure, combined with the lifelong persistence of treponemal antibodies, pushes most centers toward the same conclusion: it is simpler and safer to defer permanently than to build elaborate requalification pathways.
In the United States, the FDA requires syphilis testing on every donation. A confirmed positive typically results in permanent deferral from whole blood and direct-use components. Source plasma destined for pharmaceutical manufacturing follows a somewhat different path, which is worth understanding separately.
Source Plasma Is a Different Story
When people talk about “donating plasma,” they sometimes mean donating through a commercial plasma center where the plasma is pooled and processed into pharmaceutical products like immunoglobulins and clotting factors. This source plasma goes through industrial-scale pathogen reduction steps, including solvent-detergent treatment and nanofiltration, that are specifically designed to inactivate or remove viruses and bacteria. These manufacturing steps add a layer of safety that direct-transfusion blood products do not have.
Australia recently moved in this direction explicitly. In mid-2025, Australian Red Cross Lifeblood introduced a “plasma pathway” that allows previously ineligible individuals to donate source plasma regardless of recent sexual activity or use of HIV pre-exposure prophylaxis, because source plasma undergoes additional pathogen reduction that makes sexual-activity-based restrictions less necessary for that specific product.10PubMed. Evaluating Australia’s plasma pathway and rethinking transgender donor sexual activity restrictions In the first six months after the policy change, zero transfusion-transmissible infections were detected among donors in the new pathway.
This does not mean that syphilis-positive donors are automatically welcome at source plasma centers everywhere. Individual company policies vary, and a reactive syphilis screen will still flag your donation. But the existence of pathogen reduction in the manufacturing process is the reason some jurisdictions are beginning to take a more flexible approach to who can donate source plasma specifically.
What If You Never Had Syphilis but the Test Says You Did
False positives are a real and well-documented problem in syphilis screening. Nontreponemal tests like RPR are particularly prone to false reactivity. A range of conditions can trigger them, including autoimmune diseases, pregnancy, certain viral infections, and even the act of donating blood itself. One older study found that repeated blood donation appeared to stimulate excess reagin production in certain individuals, causing a chronic biological false positive reaction to syphilis tests that might only appear after several donations.11PubMed Central. Chronic biological false-positive reactions to serological tests for syphilis in blood donors
Even the newer treponemal tests used in the reverse algorithm are not immune to false positives, though they are more specific. A study examining donors with a reactive automated treponemal test found that when the follow-up FTA-ABS test was negative (suggesting a false positive on the initial screen), the presence of conditions traditionally associated with false positives did not significantly differ between cases and controls.12PubMed. Absence of risk factors for false-positive test results in blood donors with a reactive test result in an automated treponemal test (PK-TP) for syphilis In other words, false positives on treponemal tests can happen without any obvious explanation.
If you are deferred due to a reactive syphilis test and you have no history of syphilis, it is worth following up with your own doctor. A clinical evaluation with additional testing can often sort out whether the result was a true positive, a false positive, or evidence of a past infection you did not know about. The blood center itself may not have the resources or mandate to do this investigation for you, but having documentation from your own physician could, in some jurisdictions, support a requalification process if one exists.
Rising Syphilis Rates in the Donor Population
The strictness of syphilis screening policies exists against a backdrop of rising infection rates. In the United States, a study of roughly 14.75 million blood donations from 2020 to 2022 found a syphilis prevalence of about 28 per 100,000 donations, and prevalence was significantly higher in the second year than the first. Syphilis incidence among donors was about 11 per 100,000 person-years, and the odds of a confirmed positive syphilis result were roughly 18 percent higher in the second year of the study period compared to the first.13PubMed Central. Syphilis seroprevalence and incidence in US blood donors from 2020 to 2022
These are not large numbers in absolute terms. Donors are already a self-selected, health-conscious population, and the vast majority of donations test clean. But the upward trend mirrors what public health agencies have been seeing in the general population and makes it unlikely that blood centers will relax syphilis screening anytime soon. If anything, the trend reinforces the argument for keeping strict deferral policies in place.
Why Syphilis Raises Red Flags Beyond Syphilis
Blood banks also treat a syphilis-positive result as a marker of broader risk. The same US donor study found that donors who tested positive for syphilis were roughly 64 times more likely to also test positive for HIV than donors without syphilis.13PubMed Central. Syphilis seroprevalence and incidence in US blood donors from 2020 to 2022 A Dutch study spanning two decades of blood donor data found that unprotected sex was the dominant risk factor for both HIV and syphilis among donors, and that at post-test counseling, about 28 percent of infected repeat donors admitted to risk factors that should have permanently excluded them from donating if they had disclosed them during the screening interview.14PubMed. Two decades of risk factors and transfusion-transmissible infections in Dutch blood donors
This statistical overlap between syphilis and HIV is not a coincidence. Both infections share transmission routes, and having one makes acquiring the other biologically easier. A systematic review examining the evidence linking sexual behaviors to infection risk found strong evidence connecting a previous bacterial STI, increasing numbers of sexual partners, and chemsex to the risk of acquiring HIV and other sexually transmitted infections.15PubMed Central. Determining the strength of evidence for an association between sexual indicators and risk of acquiring HIV and sexually transmitted infections This is partly why some blood services are moving toward individualized risk assessment based on specific behaviors rather than blanket demographic categories, though that evolution is slow and syphilis remains a key screening target regardless.
Diagnosing Reinfection Is Harder Than It Sounds
One complication that affects both clinical care and donor screening is that diagnosing syphilis reinfection is genuinely difficult. If someone had syphilis, was treated, and is now potentially reinfected, the standard tests struggle. A prospective cohort study looking at IgM testing for diagnosing repeat syphilis infections found that the diagnostic sensitivity for repeat infections dropped to around 46 to 64 percent depending on the test, compared to first-time infections.16BMJ Open. Role of IgM testing in the diagnosis and post-treatment follow-up of syphilis IgM antibodies, which typically signal a new or recent infection, were simply not a reliable marker in people who had been infected before.
This matters for donor screening because it means that even if a blood center wanted to re-qualify a previously syphilis-positive donor, the available tests are not great at detecting a new infection layered on top of old antibodies from a previous one. The antibody background noise from the first infection makes it harder to spot a second. This diagnostic uncertainty is another reason centers default to permanent deferral: it is not just that they cannot prove you are cured, it is that they cannot reliably detect reinfection if it happens.
Stigma and the Experience of Being Deferred
Being told you cannot donate because of a past infection carries a psychological weight that blood collection agencies are beginning to acknowledge, even if policies have not caught up. A qualitative study exploring the donation intentions of people with infectious diseases found that privacy concerns, worry about being judged, and uncertainty about how their information would be used all limited willingness to participate in biological sample donation of any kind.17PubMed. Biosample Donation Intentions of Patients with Infectious Disease Based on the Theory of Planned Behavior For people with a treated syphilis history, the deferral can feel like a permanent mark that does not reflect their current health.
Plasma donation also carries financial implications that whole blood donation does not. In the US and some other countries, plasma donors are compensated for their time, and commercial plasma centers rely on regular donors. Permanent deferral does not just prevent someone from contributing to the blood supply; it removes a source of income for people who may have been donating regularly. Research on financial incentives and blood donation quality has found that offering compensation does not meaningfully change the rate of rejected donations, suggesting that paid donors are not inherently riskier than unpaid ones.18PubMed Central. Incentivizing Blood Donation: Systematic Review and Meta-Analysis to Test Titmuss’ Hypotheses But for the individual donor who gets screened out, the financial loss is real and immediate.
If you had syphilis in the past and want to know your specific options, the most productive step is to contact the plasma center or blood bank directly and ask about their reinstatement policy. Some commercial plasma companies have medical review processes where a physician evaluates your treatment records, current test results, and overall risk profile. These processes are not widely advertised, but they do exist at some facilities. Bring documentation of your treatment history, including the type and timing of antibiotics and any follow-up RPR results showing a declining titer. That paperwork will not guarantee reinstatement, but it gives you the best chance of a nuanced evaluation rather than a blanket refusal.